Pharmaceuticals, Biotechnology & Life Sciences

Axsome insider buy signals confidence amid volatility—12,485 new shares at $4.95 could hint at a rebound after a 52‑week low.

Insider buying surge at TriSalus signals confidence in its immunotherapy platform—executives buy shares at the public‑offering price, hinting at strong near‑term prospects.

Insider sales at Tempus AI show routine liquidity moves, not a sign of trouble – but investors should watch the new HRD‑RNA tool’s impact on earnings.

CEO‑level purchase of 400k Omeros shares signals confidence as the drug’s clinical momentum rises—what this means for investors.

Opaleye Management’s new 2.125‑million‑share stake in Alpha Cognition signals bullish confidence, highlighting the company’s patent‑driven upside potential for investors.

RA Capital’s fresh 6,200‑share purchase signals growing institutional confidence in Mineralys Therapeutics, bolstering the drug‑pipeline’s upside potential.

Rapid Micro Biosystems insider sale: CFO’s 5,403-share sell shows routine tax‑cover activity, not a market shift, but signals liquidity strategy for small‑cap biotech investors.

Insider trades at Tempus AI reveal routine tax‑withholdings, not a sell‑off, while execs still back the company’s AI‑driven oncology future.

Insider buying surge at AbbVie signals strong confidence in earnings, pipeline and capital strategy – a bullish catalyst for investors.

Kymera Therapeutics insider Esposito buys 2,500 shares at $49.10, signalling confidence amid rising pipeline headlines and potential stock rebound.